Effect of treatment guidance using a retrospective continuous glucose monitoring system on glycaemic control in outpatients with type 2 diabetes mellitus: A randomized controlled trial.

"Declaration of conflicting interest A.K. has received lecture fees from Kissei Pharma, Sanofi and Takeda Pharmaceutical Co. Y.F. has received lecture fees from Novartis Pharmaceuticals and Eli Lilly, and research funds from Novartis Pharmaceuticals, MSD, and Takeda Pharmaceutical Co. T.M. has received lecture fees from MSD, Takeda Pharmaceutical Co., and Eli Lilly. H.W. has received lecture fees from Asteras, Astrazeneca, Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Kissei Pharma, Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co., MSD, Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Mitsubishi Tanabe Pharma, Sanofi-Aventis, Sanwakagaku Kenkyusho, and Takeda Pharmaceutical Co.; and research funds from Asteras, Astrazeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo Inc., Dainippon Sumitomo Pharma, Eli Lilly, Johnson and Johnson, Kissei Pharmaceutical Co., Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co., MSD, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Pfizer, Sanwakagaku Kenkyusho, Sanofi, and Takeda Pharmaceutical Co. All other authors report no conflicts of interest."

"Funding This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (Grant Number 25350902)."

"The primary endpoint was a change in HbA1c level from baseline. The secondary endpoint was a change in the DTSQ score from baseline. The study protocol was approved by the Human Ethics Committee of Juntendo University, Tokyo, Japan (No. 25–388). Written informed consent was obtained from each patient before enrolment in the study. This study was registered with the University Hospital Medical Information Network in Japan (UMIN: 000012034)."